WHO ICTRP trial
PhaseII study of neoadjuvant chemotherapy with the nab Paclitaxel And…
JPRN-UMIN000008465 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000008465 |
|---|---|
| Public title | PhaseII study of neoadjuvant chemotherapy with the nab Paclitaxel And Trastuzumab followed by FEC for the HER2-positive resectable primary breast cancer |
| Scientific title | PhaseII study of neoadjuvant chemotherapy with the nab Paclitaxel And Trastuzumab followed by FEC for the HER2-positive resectable primary breast cancer - PhaseII study of neoadjuvant chemotherapy with the nab Paclitaxel And Trastuzumab followed by FEC for the HER2-positive resectable primary breast… |
| Primary sponsor | Osaka Breast Cancer Chemo-Endocrine Therapy Study Group |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | HER2 positive resectable primary breast cancer |
| Interventions | Administrate 4 cycles of FEC after 4 cycles of nab Paclitaxel and Trastuzumab. Operation is to be performed after chemotherapy. nab Paclitaxel and Trastuzumab 4 cycles nab Paclitaxel 260mg/m2 iv day1 q3w Trastuzumab 6 mg/kg iv day1 q3w (8… |
| Registration date | Jul 18, 2012 |
| Target size | 30 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: